The Australian landscape, in numbers
Cut Through Venture's State of Australian Startup Funding 2024 dataset gives the clearest public view of round sizes. Pre-seed median deal size: A$1 million (a record high). Seed median deal size: A$3 million (also a record high). Series A average: A$18 million, up from A$12 million in 2023. Series A volume is down even as the trigger benchmarks have tightened, meaning fewer companies make it through but the ones that do are larger.
Pre-seed and seed valuations were up roughly 11 to 12 percent year on year. Series A valuations were up around 7 percent. The implication for clinician founders is that the bar for raising at seed has not moved much, but the bar for triggering a Series A has moved up sharply.
Pre-seed: who actually writes the cheque
At pre-seed in Australia, the named institutional VCs (Blackbird, AirTree, Square Peg) write some cheques but most of the round comes from angels, accelerators, and high-net-worth individuals who have done it before. Cheque sizes are typically A$50K to A$250K from individuals, A$250K to A$750K from named pre-seed funds.
For clinician founders, the pre-seed conversation should target two profiles. Clinical-entrepreneur angels who have built and exited a healthcare company (a small but growing list in Australia). Health-adjacent VCs who can write a smaller cheque early to lock in the relationship for the seed lead conversation. The accelerator path (Startmate, particularly) remains the highest-signal credential for a clinician with no prior tech track record.
Seed round: the real numbers and the real leads
At seed, Blackbird and AirTree are the dominant Australian leads, writing A$500K to A$5 million cheques per the public profiles of both funds. Square Peg participates more selectively at seed. The check-size band that a clinician-led healthtech company should plan for is A$2 million to A$5 million for a competitive seed round in 2024-2025.
The structural feature of the Australian seed market is that the lead is almost always Australian. The follow-on capital can come from US or Asian funds, but the relationship-led nature of seed in Australia means the pre-emptive Australian fund is usually the lead. Clinician founders who try to lead-shop in the US at seed almost always lose nine to twelve months.
Series A: where the bar has moved
The A$18 million average Series A in 2024 reflects two things. The benchmarks to trigger an A have moved up across every sector, with healthtech tracking roughly A$2 to A$3 million in ARR (or equivalent for non-SaaS models) plus net revenue retention above 110 percent. And the rounds that do get done are larger because the lead is more often a US or international fund whose minimum cheque size is higher.
For clinician founders, this means two practical things. The seed runway should be planned for 24 to 30 months, not 18, because reaching the new Series A bar takes longer than it did in 2022. And the US-investor conversations should start at month six of the seed runway, not at the start of the Series A process, so that the lead conversation in the next round is not also a first conversation.
Plan the syndicate before you need it
The single highest-leverage thing a clinician founder can do during seed is to map the Series A syndicate they will run twelve to eighteen months later. Three categories of investor to track. Funds that have done at least one Series A in clinical or healthcare-adjacent companies in the previous twelve months. Funds with a partner who has clinical training or a clinical operator background. Strategic investors whose distribution would compress the company's sales cycle.
Maintain a structured monthly investor update from month one of the seed round. The update is the document the Series A is built on. The clinician founders who run a clean monthly update for twelve months arrive at the Series A with a data room that is already half-built. The clinician founders who write the first investor update only when the round is open are six to twelve weeks behind by the time the lead conversation starts.
Sources
Written by ASME Editorial · Published 15 Apr 2026